Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort

Karin Neukam, José A. Mira, Antonio Collado, Antonio Rivero-Juárez, Patricia Monje-Agudo, Josefa Ruiz-Morales, María José Ríos, Dolores Merino, Francisco Téllez, Inés Pérez-Camacho, María Carmen Gálvez-Contreras, Antonio Rivero, Juan A. Pineda, HEPAVIR SEG-HEP-2007 Study Group of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI)

1 Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain, 2 Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain, 3 Internal Medicine Service, Hospital Universitario de Valme, Seville, Spain, 4 Internal Medicine Department, Hospital Torrecárdenas, Almería, Spain, 5 Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Maimonides Institute for Biomedical Research (IMIBIC), University of Cordoba, Cordoba, Spain, 6 Unit of Infectious Diseases, Hospital Universitario Virgen de la Victoria, Malaga, Spain, 7 Unit of Infectious Diseases, Hospital Universitario Virgen de la Macarena, Seville, Spain, 8 Internal Medicine Service, Hospital Juan Ramón Jiménez. Huelva, Spain, 9 Unit of Infectious Diseases, Hospital de La Línea de la Concepción, Cadiz, Spain, 10 Unit of Tropical Medicine, Hospital Poniente, El Ejido, Spain

Abstract

Objective

to assess the current frequency of ART-associated grade 3–4 transaminase elevations (TE) and grade 4 total bilirubin elevations (TBE) in HIV-infected patients with chronic hepatitis B and/or C, who start a new regimen of ART.

Patients and Methods

A total of 192 pre-treated or treatment-naive HIV infected patients with HBV and/or HCV-coinfection who started ART in eight Southern Spanish centers from July/2011-December/2013, were followed for 12 months in this prospective study.

Results

Forty-one (21.4%) subjects had been naïve to ART, median (IQR) follow-up was 11.6 (5.6–12.9) months. The most frequently initiated NRTI were tenofovir/emtricitabine [49 patients (25.5%)]. Eighty-nine (46.4%) patients started a ritonavir-boosted protease inhibitor and 77 (40.1%) individuals a NNRTI. Raltegravir and maraviroc were initiated in 24 (12.5%) and 9 (4.7%) individuals. Ten [5.21%; 95% confidence interval (CI): 2.53%-9.37%] patients presented grade 3 TE, while 8 (4.17%; 95%CI: 1.82%-8.04%) subjects showed grade 4 TBE. No episodes of grade 4 TE or ART discontinuation due to hepatotoxic events were
the Fundación Progreso y Salud of the Junta de Andalucía (grant number RH-0024-2013). JAP is the recipient of an intensification grant from the Instituto de Salud Carlos III (grant number Programa-I3SNS).

Competing Interests: K.N. has received lecture fees from Janssen-Cilag, Roche, Bristol-Meyers Squibb and Merck Sharp & Dohme and has received research support from Janssen-Cilag, Bristol-Meyers Squibb, Merck Sharp & Dohme, Gilead Sciences and Abbott Pharmaceuticals. A.R.J has received lecture fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, ViiV Healthcare and Roche. D.M. reports having received consultancy fees from Janssen Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead Sciences, AbbVie and ViiH Healthcare. A.C. reports having received consultancy fees from Janssen-Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Gilead Sciences, Pfizer and AbbVie. A.R. reports having received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Schering-Plough, Gilead Sciences, Merck Sharp & Dohme, Boehringer Ingelheim and Johnson & Johnson. J.A.P. has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim, and has received lecture fees from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Gilead Sciences, AbbVie and ViiH. A.R.J has received lecture fees from Janssen-Cilag, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott Pharmaceuticals and Boehringer Ingelheim, and has received lecture fees from GlaxoSmithKline, Roche, Bristol-Myers Squibb, AbbVie, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. J.A.P. has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, AbbVie, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, AbbVie, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, AbbVie, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, AbbVie, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, AbbVie, Schering-Plough, Janssen-Cilag and Boehringer Ingelheim. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

observed. The use of ritonavir-boosted atazanavir was the only independent predictor for grade 4 TBE [adjusted odds ratio: 7.327 (95%CI: 1.417–37.89); p = 0.018] in an analysis adjusted for age, sex and baseline HIV-RNA levels, while no factor could be independently associated with grade 3–4 TE.

Conclusions
Currently, the frequency of severe ART-associated TE and TBE under real-life conditions in patients with chronic viral hepatitis is similar to what has been reported previously. However, episodes of grade 4 TE are less frequent and severe TE appears to be of lesser concern.

Introduction
Hepatotoxic events associated with antiretroviral drugs, including liver transaminase elevations (TE), acute liver failure and death, are of high concern in HIV-infected patients. Coinfection with hepatitis viruses can promote the development of ART-induced TE [1–6]. Nevertheless, the number of patients with HCV and/or HBV coinfection included in clinical trials on various HIV drugs that assess TE is usually low [7–12].

Data on the current rates of TE observed among HIV-infected patients with hepatitis virus coinfection obtained in the clinical practice have been described within different cohorts [1, 3–5, 13–20]. However, most of these studies have a retrospective design. Additionally, often only specific ART regimens are considered, mainly ritonavir-boosted PI (PI/r) or the NNRTI efavirenz and nevirapine [1,4,5,13,14,16,20]. Also, real-life data on some drugs, such as rilpivirine, darunavir and dolutegravir in patients with HCV-coinfection are scarce, while other studies include concomitant antiretroviral drugs that are no longer recommended. Furthermore, in some of these studies, selection criteria lead to the exclusion of subjects according to their previous regimen or liver damage, or require an optimized background ART combination. Finally, the initiation of a NRTI within an existing regimen may play a role in the development of hepatotoxic events in this setting. Therefore, due to the regimens and study populations analyzed, the studies available to date may not represent the overall situation of rapidly changing ART strategies in the clinical practice. To date, there is little information on ART-induced hepatotoxicity based on regimens and changes reflecting real-life conditions. In this context, we reported an overall frequency of grade 3–4 TE of 7.6% for a HIV/HCV-coinfected population in a multicenter cohort study conducted from 2007 to 2009 [20]. Still, no changes in NRTI strategies were evaluated and liver toxicity assessment was limited to efavirenz and PI/r in combination with two fixed NRTIs. Taken together, this information is necessary to evaluate potential liver safety differences among currently used ART. These data might be used to optimize the management of HIV-infected patients with viral hepatitis. The aim of this study was to evaluate the frequency of hepatotoxicity, determined by grade 3 or 4 TE and grade 4 total bilirubin elevations (TBE), in patients with chronic hepatitis B or C, during the first year after starting one or more currently used antiretroviral drug within one single cohort under real-life conditions.

Patients and Methods
Study Design and Population
Pre-treated or treatment-naïve HIV-infected patients who attended the Infectious Diseases Units of eight Southern Spanish centers from July 2011 to December 2013 were consecutively
included in this prospective multicentric study (ClinicalTrials.gov ID: NCT01908660) if they fulfilled the following criteria: i) older than 18 years; ii) initiation of one or more antiretroviral drugs; iii) chronic HCV infection as confirmed by HCV antibodies in plasma, as well as a positive HCV viral load determined by PCR and/or chronic HBV infection as detected by positive serum HBV surface antigen (HBsAg) and iv) absence of hepatotoxicity events two months prior to the baseline visit. Clinical visits and blood tests were scheduled at the moment of initiation of the new ART, as well as at weeks 4, 12, 24, 36 and 48. The follow-up was stopped if the patient initiated treatment against HCV or at the moment of discontinuation of one or more antiretroviral drug due to any cause.

Antiretroviral Drug Regimens
ART was indicated following the guidelines of the Spanish Group for the Study of AIDS (Grupo Español para el Estudio del SIDA, GESIDA), the Department of Health and Human Services of the USA (DHHS) or the European AIDS Clinical Society (EACS) at the time of prescription [21–23]. The final decision on the specific drug used was made according to the caring physician.

Definition of Liver Toxicity
Grade 3 and 4 TE were defined according to the baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values [24]. In patients with normal baseline transaminase levels, grade 3 TE were considered when elevations between 5 and 10 times above the upper level of normality (ULN) were observed at least one of the follow-up visits, while grade 4 TE were defined as ALT or AST values higher than 10 times of the ULN. In patients with elevated baseline transaminase levels, 3.5- to 5-fold elevations were considered grade 3 TE, and elevations higher than 5-fold were defined as grade 4 TE, respectively. Grade 4 TBE were defined as bilirubin levels exceeding 5 mg/dL.

Statistical Analysis
The outcome variable of this study was the development of grade 3 or 4 TE during follow-up. Additionally, grade 4 TBE were analyzed as secondary outcome variable. Comparative analyses of TE and TBE were carried out for the different antiretroviral drugs that were initiated in this study, as well as for age, sex and other potential factors that could influence the development of grade 3 or 4 TE or grade 4 TBE. Continuous variables were expressed as median (IQR) and were compared using the Student’s t-test for normal distribution and the Mann-Whitney U-test otherwise. Categorical variables were expressed as number [percentage; 95% confidence interval (CI)] and were analyzed by means of the χ²-test or the Fisher’s test, when applicable. In order to compare the CD4 cell counts and the HIV viral loads at baseline and the end of follow-up, the Wilcoxon Signed Rank test and the McNemar test were applied, respectively. Finally, a logistic regression model was created with those factors that showed an association with the outcome variables in the univariate analysis with a p<0.2, as well as age and sex, in order to identify independent risk factors for the outcome variables. The adjusted odds ratios and the respective 95% CI were calculated. Statistical analysis was performed using the SPSS statistical software package release 22.0 (IBM, Chicago, IL, USA) and STATA 9.0 (StatCorp LP, College Station, TX, USA).

Ethical Aspects
The study was designed and performed according to the Helsinki declaration and was approved by the Ethics Committee of the Valme University Hospital (Seville, Spain; approval
reference number: 4/2011) and the Spanish Agency for Drugs and Sanitary Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS). All patients gave their written informed consent before being included in the study.

Results

Study Population

A total of 192 patients were included in the analysis. The median (IQR) follow-up of the study population was 11.6 (5.6–12.9) months and the median (IQR) nadir CD4 cell count was 183 (67.8–274) cells/mL. Sixty-five (33.9%) individuals had received treatment against HCV infection without reaching sustained virologic response. Of these, 38 (58.5%) were non-responders, 8 (12.3%) had discontinued due to adverse events, 7 (10.8%) individuals had relapsed and 4 (6.2%) patients had developed a virologic breakthrough. The remaining 8 (12.3%) patients had dropped out voluntarily. Patient characteristics at the moment of starting a new ART combination are displayed in Table 1. Forty-one (21.4%) individuals started the new ART due to virologic failure, 55 (28.6%) patients due to adverse events to prior ART and 41 (21.4%) individuals had been ART-naïve. Simplification was the reason for switching in 29 (15.1%) individuals and in 20 (10.4%) patients changes were applied in order to avoid pharmacologic interactions with future therapy against HCV infection or other drugs. The remaining 6 (3.6%) changes were due to various reasons.

Newly Introduced Drugs and Resulting ART

A total of 342 drug initiations were registered. Among the newly introduced regimens, 77 (40.1%) involved a NRTI, 89 (46.4%) a PI/r and 77 (40.1%) a NNRTI, respectively. The detailed

| Characteristic                          | Value            |
|----------------------------------------|------------------|
| Male sex, n (%)                        | 169 (88)         |
| Age, years*                            | 46.4 (42.9–50.6) |
| Prior injection drug users, n (%)      | 150 (78.1)       |
| Alcohol consumption ≥ 50 g/day, n (%)  | 30 (15.6)        |
| CDC category C, n (%)                  | 63 (32.8)        |
| CD4 cell count, cells/mL*              | 393 (239–566)    |
| Undetectable HIV viral load, n (%)     | 77 (40.1)        |
| HCV-RNA (+)/HBsAg (-), n(%)            | 182 (94.8)       |
| HCV-RNA (-)/HBsAg (+), n (%)           | 9 (4.7)          |
| HCV-RNA (+)/HBsAg (+), n(%)            | 1 (0.5)          |
| ALT*, IU/mL                            | 50 (33–76.8)     |
| AST*, IU/mL                            | 46 (32.3–71.8)   |
| Total bilirubin*, mg/dL                | 0.63 (0.44–0.9)  |
| Liver stiffness*, kPa                   | 8.5 (6.7–14.8)   |
| Advanced fibrosis, n (%)§              | 84 (43.8)        |
| Cirrhosis, n (%)§                      | 55 (28.6)        |
| Patients with hepatic decompensations prior to study, n (%)§ | 9 (4.7) |

*Median (interquartile range)
§determined by transient elastometry: cut-off values were 9.5 kPa for advanced fibrosis and 14.6 kPa for cirrhosis
§number of events: ascites: 5, hepatic encephalopathy: 4, variceal hemorrhage: 2, jaundice: 1, hepatocarcinoma: 2.

doi:10.1371/journal.pone.0148104.t001
proportions of the drugs within these groups that were subject to change are displayed in Table 2. The majority [157 patients (81.8%)] received triple therapy. Eighteen subjects (9.4%) received dual therapy, 11 (5.7%) individuals received monotherapy, and a regimen consisting of four drugs was administered in 6 (3.1%) subjects.

Follow-Up

One-hundred and fourteen (59.4%) patients remained with the new ART until the end of the study follow-up of 48 weeks. The detailed reasons for ART discontinuation or premature stop of follow-up are depicted in Fig 1. The proportion of patients with undetectable HIV RNA was 40% (77/192 patients) at baseline and 81.6% (93/114 individuals) among those who reached the end of follow-up (p<0.001). CD4 levels (IQR) changed from 393 (239–566) cells/mL at baseline to 472 (298–712) cells/mL at the end of follow-up (p = 0.006). Liver safety. A total of 10 (5.21%; 95%CI: 2.53%-9.37%) individuals developed grade 3 TE: 9 (4.9%) of the HIV/HCV-coinfected patients versus 1 (11.1%) of the HIV/HBV-coinfected individuals. No case of grade 4 TE was observed. Regimens and coinfection status of these patients are listed in Table 3. TBE was observed in 8 (4.17%; 95%CI: 1.82%-8.04%) patients, all of whom were HCV-coinfected and none showed HBV infection. Five (62.5%) individuals who presented TBE received ART based on ritonavir-boosted atazanavir and one respective patient received ritonavir-boosted darunavir, raltegravir or rilpivirine. No patient discontinued therapy due to hepatotoxic events. Liver decompensations during follow-up were developed by 8 (4.2%) patients, none of whom presented grade 3 or 4 TE or grade 4 TBE. In the multivariate analysis (Table 4), no factor was independently associated with grade 3 or 4 TE. The use of ritonavir-boosted atazanavir was the only independent predictor for grade 4 TBE.

Discussion

To our knowledge, this is the first study to evaluate the hepatic safety of current ART administered in clinical practice within a single prospective cohort consisting of a large sample of

Table 2. Newly introduced antiretroviral therapy (ART).

| Antiretroviral drug                                      | n (%) |
|----------------------------------------------------------|-------|
| Nucleoside analogue reverse transcriptase inhibitors (NRTI) |       |
| Tenofovir/emtricitabine                                  | 49 (25.5) |
| Abacavir/ lamivudine                                     | 14 (7.3) |
| Other NRTI combinations                                  | 14 (7.3) |
| NRTI-sparing                                             | 115 (59.9) |
| Ritonavir-boosted protease inhibitors                    |       |
| Lopinavir/ritonavir                                      | 11 (5.7) |
| Atazanavir/ritonavir                                     | 25 (13) |
| Darunavir/ritonavir                                      | 53 (27.6) |
| Non-nucleoside analogue reverse transcriptase inhibitors |       |
| Efavirenz                                                | 18 (9.4) |
| Nevirapine                                               | 7 (3.6) |
| Etravirine                                               | 16 (8.3) |
| Rilpivirine                                              | 36 (18.8) |
| Integrase inhibitors                                     |       |
| Raltegravir                                              | 24 (12.5) |
| Entry inhibitors                                         |       |
| Maraviroc                                                | 9 (4.7) |

doi:10.1371/journal.pone.0148104.t002
patients with chronic viral hepatitis. The frequency of grade 3 or 4 TE, as well as grade 4 TBE, associated with frequently used antiretroviral drug combinations in clinical practice is low in this setting.

Table 3. Patient characteristics of those who suffered grade 3 or 4 transaminase elevations (TE).

| No. | Previous regimen | New regimen | Months to TE | Grade of TE | Anti-HCV | HBsAg |
|-----|------------------|-------------|--------------|-------------|----------|-------|
| 1   | TDF/FTC/ETV      | LPV/r       | 3            | 3           | pos      | neg   |
| 2   | TDF/3TC/ATV/r    | DRV/r/RAL   | 12           | 3           | pos      | neg   |
| 3   | naive            | TDF/FTC/ATV/r | 1           | 3           | pos      | neg   |
| 4   | TDF/FTC/LPV/r    | DRV/r       | 12           | 3           | pos      | neg   |
| 5   | naive            | TDF/FTC/ATV/r | 3           | 3           | pos      | neg   |
| 6   | TDF/FTC/EFV      | ABV/FTC/EFV | 9            | 3           | pos      | neg   |
| 7   | TDF/FTC/FPV/r    | TDF/FTC/DRV/r | 1           | 3           | pos      | neg   |
| 8   | DRV/r/ETV/RAL    | DRV/r/ETV/MVC | 3           | 3           | pos      | neg   |
| 9   | TDF/FTC/EFV      | TDF/FTC/NVP | 3            | 3           | pos      | neg   |
| 10  | naive            | TDF/FTC/DRV/r | 1           | 3           | neg      | pos   |

TDF: tenofovir; FTC: emtricitabine; ETV: etravirine; LPV/r: ritonavir-boosted lopinavir; 3TC: lamivudine; ATV/r: ritonavir-boosted atazanavir; DRV/r: ritonavir-boosted darunavir; RAL: raltegravir; EFV: efavirenz; ABV: abacavir; FPV/r: ritonavir-boosted fosamprenavir; MVC: maraviroc; NVP: nevirapine.

doi:10.1371/journal.pone.0148104.t003
Table 4. Univariate and multivariate analysis of factors associated with grade 3 or 4 transaminase elevations (TE) and grade 4 total bilirubin elevations (TBE).

|                  | Grade 3 or 4 TE, n (%) | p       | AOR (95% CI) | Grade 4 TBE, n (%) | p       | AOR (95% CI) |
|------------------|------------------------|---------|--------------|--------------------|---------|--------------|
| **Age**          |                        |         |              |                    |         |              |
| <46 years        | 96                     | 7 (7.3) | 0.194        | 1.027              | 0.57    | 5 (5.2)      | 0.360        | 1.052 | 0.438 |
| ≥46 years        | 96                     | 3 (3.1) | (0.936–1.127)| 3 (3.1)            | (0.926–1.193)|          |
| **Sex**          |                        |         |              |                    |         |              |
| Male             | 169                    | 9 (5.3) | 0.658        | 1.073              | 0.949   | 7 (4.1)      | 0.647        | 1.297 | 0.826 |
| Female           | 23                     | 1 (4.3) | (0.124–9.303)| 1 (4.3)            | (0.127–13.225)|          |
| **Alcohol intake**|                       |         |              |                    |         |              |
| <50 g/day        | 162                    | 7 (4.3) | 0.192        | 0.387              | 0.202   | 8 (4.9)      | 0.250        |        |
| ≥50 g/day        | 30                     | 3 (10)  | (0.09–1.66)  |                    |         |              |
| **ALT levels**   |                        |         |              |                    |         |              |
| ≥40 IU/mL        | 121                    | 7 (5.8) | 0.458        |                    |         |              |
| <40 IU/mL        | 71                     | 3 (4.2) | (0.09–1.66)  |                    |         |              |
| **CDC category C**|                       |         |              |                    |         |              |
| Yes              | 63                     | 3 (4.8) | 0.574        |                    |         |              |
| No               | 129                    | 7 (5.4) | (0.34–9.30)  |                    |         |              |
| **Undetectable HIV RNA** |                 |         |              |                    |         |              |
| Yes              | 77                     | 3 (3.9) | 0.376        |                    |         |              |
| No               | 115                    | 7 (6.1) | (0.17–26.6)  |                    |         |              |
| **CD4 cell count**|                       |         |              |                    |         |              |
| <350 cells/mL    | 81                     | 5 (6.2) | 0.421        |                    |         |              |
| ≥350 cells/mL    | 111                    | 5 (4.5) | (0.269–6.475)|                    |         |              |
| **Baseline cirrhosis** |                |         |              |                    |         |              |
| Yes              | 55                     | 2 (3.6) | 0.415        |                    |         |              |
| No               | 137                    | 8 (5.8) | (0.25–26.5)  |                    |         |              |
| **Start of a NRTI** |                     |         |              |                    |         |              |
| Yes              | 77                     | 3 (3.9) | 0.503        |                    |         |              |
| No               | 115                    | 3 (4.5) | (0.24–9.30)  |                    |         |              |
| **Start of a PI/r** |                     |         |              |                    |         |              |
| Yes              | 89                     | 7 (7.9) | 0.124        | 1.319              | 0.733   | 4 (4.5)      | 1           |        |
| No               | 103                    | 3 (2.9) | (0.269–6.475)|                    |         |              |
| **Use of ATV/r** |                        |         |              |                    |         |              |
| Yes              | 29                     | 2 (6.9) | 0.649        |                    |         |              |
| No               | 163                    | 8 (4.9) | (0.269–6.475)|                    |         |              |
| **Start of a NNRTI** |                      |         |              |                    |         |              |
| Yes              | 77                     | 1 (1.3) | 0.052        | 0.183              | 0.748   | 1 (1.3)      | 0.147        | 0.397 | 0.43 |
| No               | 115                    | 9 (7.8) | (0.017–1.925)| 7 (6.1)            | (0.04–3.932)|          |
| **Start of RAL** |                        |         |              |                    |         |              |
| Yes              | 24                     | 1 (4.2) | 0.683        |                    |         |              |
| No               | 168                    | 9 (5.4) | (0.269–6.475)|                    |         |              |
| **Start of a MVC** |                      |         |              |                    |         |              |
| Yes              | 9                      | 1 (11.1)| 0.389        |                    |         |              |
| No               | 183                    | 9 (4.9) | (0.269–6.475)|                    |         |              |

AOR: adjusted odds ratio; CI: confidence interval; NRTI: nucleot(s)ide reverse transcriptase inhibitor; PI/r: ritonavir-boosted protease inhibitor; ATV/r: ritonavir-boosted atazanavir; NNRTI: non-nucleot(s)ide reverse transcriptase inhibitor; RAL: raltegravir; MVC: maravi

doi:10.1371/journal.pone.0148104.t004
To date, little information on hepatic safety of multiple ART regimens under current real-life conditions is available [4,5,20]. Our group reported in 2011 a frequency of 7.6% of grade 3 to 4 TE among HIV/HCV-coinfected patients, with no impact of the ART applied [20]. However, only efavirenz and PI/r were considered in this study, and the number of patients who received ritonavir-boosted atazanavir and ritonavir-boosted darunavir was low. Thus, that cohort does not reflect the current situation and indeed, in the present study, ritonavir-boosted atazanavir and ritonavir-boosted darunavir represent the most frequently prescribed PI/r, which is in accordance with international guidelines applied during the inclusion period, while potentially hepatotoxic drugs like saquinavir [25] and fosamprenavir [26] were not among the applied regimens. Furthermore, a considerable proportion of the patients received newer NNRTI, as well as maraviroc and raltegravir. It is to note that the frequencies of grade 3 or 4 TE and grade 4 TBE are low in this setting and was to be contributed to a specific drug. Furthermore, the frequencies of these hepatotoxicity events have decreased as compared to what was observed in a similar population from 2007 to 2009, analysed in the same centers and with a comparable study design [20], although they are somewhat higher as described in a different cohort [6]. Currently used ART can generally be considered to be well tolerated. In fact, no grade 4 TE was observed, and no discontinuation due to TE or TBE was reported. These are important findings, since they imply that the frequency of hepatotoxic events in HIV/HBV- and/or HCV-coinfected has decreased with the newer regimens as compared to what was reported at the beginning of the era of highly active ART [27–30]. Finally, the outcome of TE is good and discontinuations are of lesser concern, which results in a lower exploitation of treatment options and an augmentation of life quality for the patient.

In the history of safety studies involving antiretroviral drugs, the question of whether the presence of advanced fibrosis has an impact on the prevalence of ART-induced hepatotoxic events has risen especially regarding the hepatitis virus coinfected population [31,32]. However, various cohort studies published afterwards failed to confirm a relationship between the fibrosis stage and liver enzyme elevations in patients treated with various regimens [14–16,19,20] and an impact of advanced liver damage on grade 3 or 4 TE is therefore unlikely. Nevertheless, especially cirrhotic patients may have plasma levels of antiretrovirals that are above the safety concentration and HCV infection itself may have an impact on plasma levels of ART components such as ritonavir-boosted atazanavir, efavirenz and etravirine [33–35]. In the present study, a considerably high number of patients were administered the antiretroviral drugs susceptible to suffer plasma level elevations due to advanced liver disease. It is to point out that no association between cirrhosis at baseline and grade 3 or 4 TE or grade 4 TBE was observed.

A considerable number of patients started a new ART regimen with the prospect of possible initiation of treatment against HCV infection. This is not surprising since the study was conducted at the beginning of the era of direct-acting antivirals (DAA) against hepatitis C. In this context, in 2012, the protease inhibitors telaprevir and boceprevir were the first DAA approved for treatment against chronic hepatitis C in HIV/HCV-coinfected patients in Europe [23]. Unfortunately, drug-drug interactions resulted in contraindications for the concomitant use of these drugs with ritonavir-boosted lopinavir or ritonavir-boosted darunavir and required dose adjustments of telaprevir if ART included efavirenz [36,37]. Although with the next-generation DAA drug-drug interactions may be of lesser concern, this issue remains an important consideration, especially regarding HCV PI and will likely be reflected in the composition of future ART regimens [23]. In the present study, the considerably high proportion of patients who initiated ritonavir-boosted atazanavir account for this finding. We point out that the use of ritonavir-boosted atazanavir was independently associated with grade 4 TBE, which stands in accordance with former studies [13,38,39]. However, atazanavir-induced hyperbilirubinemia
did not lead to treatment interruptions and was not associated with the clinical outcome of ART in the short and the long term [38,39]. Although bilirubin levels should be monitored in this setting, a clinical impact of this phenomenon is unlikely.

Sustained virological response to therapy against HCV infection leads to a marked decrease in the risk of drug-related liver toxicity in HIV/HCV-coinfected patients [40]. This fact prompted the recommendation of treating hepatitis C before HIV-infection in subjects with high CD4 cell count [21–23]. However, as shown here, the risk of severe liver toxicity with the currently used drugs is very low. In addition, the results of the START Study [41] support immediate ART after HIV infection diagnosis. Because of these reasons, and given that the interactions of antiretroviral drugs and direct-acting antivirals are manageable, in our opinion, deferring ART until having treated chronic hepatitis C infection is no longer justified in HIV/HCV-coinfected subjects.

This study has limitations. Due to the high variety of possible ART regimens, some drugs were applied to a lesser extent. Still, the antiretroviral drugs approved at the time of the recruitment of patients were administered in an adequate number and the composition of the regimens studied herein well reflect the situation of ART during the inclusion period. Finally, most recently approved drugs like dolutegravir and elvitegravir/cobicistat were not available during patient recruitment and should be considered in future study designs.

In conclusion, currently applied ART regimens can be considered safe in HIV-infected patients with viral hepatitis and advanced liver damage did not impact on the development of severe laboratory abnormalities analyzed herein. Although the frequencies are similar to what has been reported previously, the severity of hepatotoxic side effects have decreased throughout the last years and are unlikely to lead to treatment discontinuations.

Acknowledgments

Other members of the HEPAVIR SEG-HEP-2007 Study Group are: Ángela Camacho, Emilio Campos Dávila, Francisco Javier Casas Ciria, Mario Casas-Frias, Francisca Cuenca, Elisa Fernández Fuertes, Africa García Navarrete, María José Garrido Vega, Ana Gordon, Diego Rodríguez-Cano, Juan Macias, María Mancebo, Manuel Márquez, Sandra Lorenzo Moncada, Montserrat Pérez Pérez, Miguel Raffo Márquez, José Carlos Roldán Morales, Enrique Nuño, Guillermo Ojeda, Rosario Palacios and Jesús Santos.

Author Contributions

Conceived and designed the experiments: KN JAM JAP. Performed the experiments: KN JAM AC ARJ PMA JRM MJR DM FT IPC MCGC AR JAP. Analyzed the data: KN JAM JAP. Contributed reagents/materials/analysis tools: KN JAM AC ARJ PMA JRM MJR DM FT IPC MCGC AR JAP. Wrote the paper: KN JAM AC ARJ PMA JRM MJR DM FT IPC MCGC AR JAP.

References

1. Di Biagio A, Nicolini LA, Lorenzini P, Puoti M, Antinori A, Cozzi-Lepri A, et al. (2014) Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort. HIV Clin Trials; 15: 151–160. doi:10.1310/hct1504-151 PMID: 25143024
2. Ha B, Wine B, Rodriguez-Alcantra F, Shafer M. (2012) Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection. HIV Clin Trials; 13: 171–177. doi: 10.1310/hct1303-171 PMID: 22592097
3. Hurt CB, Napravnik S, Moore RD, Eron JJ Jr. (2014) Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C. Antivir Ther; 19: 415–422. doi: 10.3851/IMP2738 PMID: 24458137
Liver Safety of Current ART in Viral Hepatitis Coinfection

4. Van Welzen B, Mudrikova T, Arends J, Hoepelman A. (2012) No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients. HIV Med; 13: 448–452. doi: 10.1111/j.1468-1293.2012.00995.x PMID: 22413955

5. Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, et al. (2015) Risk of Liver Enzyme Elevation during Treatment with Ritonavir-boosted Protease Inhibitors among HIV-Mono-infected and HIV/HCV Coinfected Patients. J Acquir Immune Defic Syndr; 69: 312–318. doi: 10.1097/QAI.0000000000000585 PMID: 25723139

6. Vispo E, Fernández-Montero JV, Labarga P, Barreiro P, Soriano V. (2013) Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-1/HIV-C virus coinfected patients. AIDS; 27: 1187–1188. doi: 10.1097/QAD.0b013e32835cb815 PMID: 23739226

7. Molina JM, Andrade-Villanueva J, Echevarría J, Chetchotisakd P, Corral J, David N, et al. (2014) Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1); a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet; 383: 1474–1482. doi: 10.1016/S0140-6736(13)62187-X PMID: 24522178

8. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Ciunack N, Liu YP, et al. (2012) Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis; 12: 27–35. doi: 10.1016/S1473-3099(11)70249-3 PMID: 22015077

9. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. (2013) Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis; 13: 927–935. doi: 10.1016/S1473-3099(13)70257-3 PMID: 24074642

10. Lennox JL, Landovitz RJ, Ribaudo H, Ofotokun I, Na LH, Godfrey C, et al. (2014) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med; 161: 461–471. doi: 10.7326/M14-1084 PMID: 25285539

11. Orkin C, DeJesus E, Khandlau H, Stoehr A, Supparatpinyo K, Lathouwers E, et al. (2013) Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med; 14: 49–59.

12. Pineda JA, Santos J, Rivero A, Abdel-Kader L, Palacios R, Camacho A, et al. (2008) Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother; 61: 925–932. doi: 10.1093/jac/dkn045 PMID: 18276600

13. Rockstroh J, Teppher H, Zhao J, Sklar P, Harvey C, Strommaier K, et al. (2012) Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med; 13: 127–131. doi: 10.1111/j.1468-1293.2011.00933.x PMID: 21599819

14. Palacios R, Vergara S, Rivero A, Aguilar I, Macías J, Camacho A, et al. (2006) Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials; 6: 319–323.

15. Macias J, Neukam K, Portilla J, Iribarren JA, de Los Santos I, Rivero A, et al. (2011) Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother; 66: 1346–1350. doi: 10.1093/jac/dkr083 PMID: 21398295

16. Macias J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, et al. (2012) Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. HIV Clin Trials; 13: 61–69. doi: 10.1310/hct1302-61 PMID: 22510353

17. Lazzarin A, Than S, Valluri SR, Heera J, Mukwaya G. (2012) Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program. HIV Clin Trials; 13: 83–99. doi: 10.1310/hct1302-83 PMID: 22510355

18. Taramasso L, Madeddu G, Ricci E, De Socio GV, Menzaghi B, Orfino G, et al. (2015) Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomed Pharmacother; 69: 233–236. doi: 10.1016/j.biopha.2014.12.006 PMID: 25661363

19. Casado JL, Mena A, Bañón S, Moreno A, Castro A, Perez-Eliás MJ, et al. (2014) Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis. J Int AIDS Soc; 17: 19574. doi: 10.7448/IAS.17.4.19574 PMID: 25394081

20. Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, et al. (2011) Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother; 66; 2605–2614. doi: 10.1093/jac/dkr357 PMID: 21903660
21. Grupo de Estudio del SIDA. GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus. Available: http://www.gesida-seimc.org/guias_clinicas.php?mn_MP=406&mn_MS=407. Accessed 25 November 2015.

22. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 25 November 2015.

23. European AIDS Clinical Society (EACS). Clinical Management and Treatment of Chronic HBV and HCV Co-infection in HIV-positive Persons. Available: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed 25 November 2015.

24. National Institute of Allergy and Infectious Diseases. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events 2004. Available: http://aidsinfo.nih.gov/labsandresources/resources/daidsclinrsrch/documents/daidaegradingtable.pdf. Accessed 25 November 2015.

25. Gisolf EH, Dreezen C, Danner SA, Weel JL, Mehta SH, Chaisson RE, Moore RD. (2012) Hepatotoxicity associated with ritonavir/lopinavir in HIV-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis; 5: 1234–1239.

26. Merchante N, López-Cortés LF, Delgado-Fernández M, Rios-Villegas MJ, Márquez-Solero M, Merino D, et al. (2011) Low incidence of severe hepatic toxicity with 1400/100mg OD fosamprenavir/ritonavir in HIV/HCV-coinfected patients. The TEL-C study. AIDS Patients Care STDS; 25: 395–402.

27. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. (2002) Hepatotoxicity associated with atazanavir and other determinants of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CAS-TLE study. AIDS Patients Care STDS; 26: 259–264. doi: 10.1089/apy.2011.0092 PMID: 22404426

28. Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, et al. (2005) Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatitis toxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis; 40: 588–593. PMID: 15712082

29. Mira JA, Macías J, Girón-González JA, Merino D, González-Serrano M, Jiménez-Mejías ME, et al. (2006) Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother; 58: 140–146. PMID: 16720565

30. Barreiro P, Rodríguez-Novoa S, Labarga P, Ruiz A, Jiménez-Nácher I, Martín-Carbonero L, et al. (2007) Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis; 195: 973–979. PMID: 17307878

31. Calza L, Danese I, Colangeli V, Manfredi R, Magistrelli E, Verucchi G, et al. (2015) Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. Infect Dis (Lond): 1–12.

32. Regazzi M, Villani P, Guimetti R, Cusato M, Tinelli C, et al. (2011) Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Ther Drug Monit; 33: 303–308. doi: 10.1097/FTD.0b013e31821c2772 PMID: 21544015

33. Vertex Pharmaceuticals. Incivek (Telaprevir) prescribing information. Available: http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed 25 November 2015.

34. Sharp M & Dohme. Victril (Boceprevir) prescribing information. Available: https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf. Accessed 25 November 2015.

35. McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, et al. (2012) Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CAS-TLE study. AIDS Patients Care STDS; 26: 259–264. doi: 10.1089/apy.2011.0092 PMID: 22404426

36. Laprise C, Baril JG, Dufresne S, Trottier H. (2013) Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up. AIDS Patient Care STDS; 27: 378–386. doi: 10.1089/apy.2013.0009 PMID: 23829329

37. Labarga P, Soriano V, Vispo ME, Pinilla J, Martín-Carbonero L, Castellares C, et al. (2007) Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis; 196: 670–676. PMID: 17674307
41. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. (2015) Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med; 373: 795–807. doi: 10.1056/NEJMoa1506816 PMID: 26192873